<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Nitrous oxide: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Nitrous oxide: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Nitrous oxide: Drug information</div><div class="clear"></div><div id="topicText"><div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
(For additional information <a class="drug drug_patient" data-topicid="12089" href="/d/html/12089.html" rel="external">see "Nitrous oxide: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F201351"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Dental Gases;</li>
<li>
                        General Anesthetic</li></ul></div>
<div class="block doa drugH1Div" id="F201344"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="49d8e23a-f280-4ab7-b608-f374f78a6522">Surgical sedation and analgesia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Surgical sedation and analgesia (adjunctive agent): Note:</b> Minimal alveolar concentration, which can be considered the ED<sub>50</sub> of inhalational anesthetics, is ~104% to 105%; therefore, delivery in a hyperbaric chamber is necessary to use as a sole agent for complete anesthesia. Use decreases requirements of other inhaled or IV anesthetics (ESA [Buhre 2019]; Gropper 2020).</p>
<p style="text-indent:-2em;margin-left:4em;">Procedural sedation: <b>Inhalation:</b> Concentrations of 30% to 50% nitrous oxide with oxygen (Bahn 2005; ESA [Buhre 2019]).</p>
<p style="text-indent:-2em;margin-left:4em;">General anesthesia: <b>Inhalation:</b> Concentrations of 50% to 70% via mask or endotracheal tube (ESA [Buhre 2019]; Gropper 2020; Myles 2007; Myles 2014).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b7aced04-456c-475f-9718-0486a26617f1">Dental sedation and analgesia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Dental sedation and analgesia:</b>
<b>Inhalation:</b> Concentrations of 30% to 50% nitrous oxide with oxygen (ESA [Buhre 2019]; Gropper 2020).</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F56764934"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doha drugH1Div" id="F56764935"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doe drugH1Div" id="F201345"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F201347"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block adr drugH1Div" id="F201326"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">There are no adverse reactions listed in the manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Depression of myocardial contractility (Brodsky 1986), hypotension (Brodsky 1986)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Homocystinemia (Zafirova 2018)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Nausea and vomiting (including severe nausea and vomiting) (Myles 2014, Zafirova 2018)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Cognitive dysfunction (including psychomotor impairment and slowed reaction time) (Brodsky 1986), disorientation (Brodsky 1986), hysteria (Brodsky 1986), paresthesia (Brodsky 1986)</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: <b></b>Increased middle ear pressure (with transient auditory impairment, hemotympanum, otalgia, and perforated tympanic membrane) (Brodsky 1986, Ohryn 1995), tinnitus (Brodsky 1986)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Atelectasis (Sun 2015), hypoxia (Brodsky 1986)</p></div>
<div class="block coi drugH1Div" id="F201334"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Although there are no contraindications listed in the manufacturer's labeling, use of nitrous oxide should be avoided in the following situations: patients with disorders of vitamin B<sub>12</sub> deficiency, folate, or methionine synthesis or metabolism; patients having undergone vitreoretinal surgery and presence of intraocular gas bubble; and patients with pneumothorax, pneumocephalus, and closed dura, or those at high risk for vascular air embolus (ESA [Buhre 2019]; Fu 2002; Gropper 2020; Lee 2004).</p></div>
<div class="block war drugH1Div" id="F201324"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Body space volume expansion: Both compliant (eg, bowel gas, pneumothorax) and poorly compliant (eg, middle ear) body spaces may be prone to changes in volume due to nitrous oxide transfer; avoid use in pneumothorax, pneumocephalus, middle ear surgery, or bowel obstruction (Miller 2010; Ohryn 1995; Sprehn 1992).</p>
<p style="text-indent:-2em;margin-left:4em;">• Bone marrow suppression: Prolonged use may produce bone marrow suppression; patients with vitamin B<sub>12</sub> deficiency (pernicious anemia) and those with other nutritional deficiencies (patients with alcohol use disorder) are at increased risk (ESA [Buhre 2019]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Nausea/vomiting: Occurs postoperatively in ~15% of patients (Sun 2015); risk may be reduced by antiemetics (Myles 2016).</p>
<p style="text-indent:-2em;margin-left:4em;">• Neurologic effects: Prolonged use may produce neurologic dysfunction; patients with vitamin B<sub>12</sub> deficiency (pernicious anemia) and those with other nutritional deficiencies (patients with alcohol use disorder) are at increased risk.</p>
<p style="text-indent:-2em;margin-left:4em;">• Substance use disorder: May be associated with abuse and/or substance use disorder (Zafirova 2018).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Vitreoretinal surgery: Detached retina and other ocular disorders treated with vitreoretinal surgery where intraocular gas was used: Nitrous oxide can increase intraocular pressure which may result in retinal artery occlusion, ischemia, or optic nerve damage and vision loss in these patients. Nitrous oxide should not be used in patients who have had an intravitreal gas bubble unless it can be confirmed that the bubble has been completely resorbed (Fu, 2002; Lee, 2004).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Handling: Never allow any unprotected part of the body to touch uninsulated pipes or vessels that contain cryogenic liquids.</p>
<p style="text-indent:-2em;margin-left:4em;">• Oxygen use: Oxygen should be administered for several minutes before and after discontinuing nitrous oxide to prevent diffusion hypoxia (Gropper 2020).</p></div>
<div class="block foc drugH1Div" id="F201330"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">Supplied in blue cylinders</p></div>
<div class="block geq drugH1Div" id="F201320"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block use drugH1Div" id="F201331"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Sedation and analgesia: </b>Sedation, analgesia, and amnesia; principal adjunct to inhalation and intravenous general anesthesia.</p></div>
<div class="block mst drugH1Div" id="F5977825"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drug classes which have a heightened risk of causing significant patient harm when used in error. </p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299770"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F201327"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alizapride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Azelastine (Nasal): May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Blonanserin: CNS Depressants may enhance the CNS depressant effect of Blonanserin.  Management: Use caution if coadministering blonanserin and CNS depressants; dose reduction of the other CNS depressant may be required. Strong CNS depressants should not be coadministered with blonanserin.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brexanolone: CNS Depressants may enhance the CNS depressant effect of Brexanolone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brimonidine (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromopride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromperidol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BUPivacaine: Nitrous Oxide may enhance the adverse/toxic effect of BUPivacaine. Specifically, the risk of methemoglobinemia may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of other CNS depressants, and avoiding such drugs in patients at high risk of buprenorphine overuse/self-injection. Initiate buprenorphine at lower doses in patients already receiving CNS depressants.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabinoid-Containing Products: CNS Depressants may enhance the CNS depressant effect of Cannabinoid-Containing Products. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlormethiazole: May enhance the CNS depressant effect of CNS Depressants. Management: Monitor closely for evidence of excessive CNS depression. The chlormethiazole labeling states that an appropriately reduced dose should be used if such a combination must be used.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlorphenesin Carbamate: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dapsone (Topical): May enhance the adverse/toxic effect of Methemoglobinemia Associated Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Daridorexant: May enhance the CNS depressant effect of CNS Depressants. Management: Dose reduction of daridorexant and/or any other CNS depressant may be necessary. Use of daridorexant with alcohol is not recommended, and the use of daridorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">DexmedeTOMIDine: CNS Depressants may enhance the CNS depressant effect of DexmedeTOMIDine.  Management: Monitor for increased CNS depression during coadministration of dexmedetomidine and CNS depressants, and consider dose reductions of either agent to avoid excessive CNS depression.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Difelikefalin: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dimethindene (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Doxylamine: CNS Depressants may enhance the CNS depressant effect of Doxylamine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DroPERidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (eg, opioids, barbiturates) with concomitant use.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Esketamine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flunarizine: CNS Depressants may enhance the CNS depressant effect of Flunarizine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flunitrazepam: CNS Depressants may enhance the CNS depressant effect of Flunitrazepam.  Management: Reduce the dose of CNS depressants when combined with flunitrazepam and monitor patients for evidence of CNS depression (eg, sedation, respiratory depression). Use non-CNS depressant alternatives when available.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants. Management: Consider a decrease in the CNS depressant dose, as appropriate, when used together with hydroxyzine. Increase monitoring of signs/symptoms of CNS depression in any patient receiving hydroxyzine together with another CNS depressant.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Isoflurane: May enhance the CNS depressant effect of Nitrous Oxide. Nitrous Oxide may enhance the therapeutic effect of Isoflurane. Specifically, isoflurane MAC values may be decreased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ixabepilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kava Kava: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kratom: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lemborexant: May enhance the CNS depressant effect of CNS Depressants. Management: Dosage adjustments of lemborexant and of concomitant CNS depressants may be necessary when administered together because of potentially additive CNS depressant effects. Close monitoring for CNS depressant effects is necessary.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lisuride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Local Anesthetics: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Local Anesthetics. Specifically, the risk for methemoglobinemia may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lofexidine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methotrexate: Nitrous Oxide may enhance the adverse/toxic effect of Methotrexate. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce the usual dose of CNS depressants by 50% if starting methotrimeprazine until the dose of methotrimeprazine is stable. Monitor patient closely for evidence of CNS depression.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Metoclopramide: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">MetyroSINE: CNS Depressants may enhance the sedative effect of MetyroSINE. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Minocycline (Systemic): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nabilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitric Oxide: May enhance the adverse/toxic effect of Methemoglobinemia Associated Agents. Combinations of these agents may increase the likelihood of significant methemoglobinemia.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olopatadine (Nasal): May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Opioid Agonists: CNS Depressants may enhance the CNS depressant effect of Opioid Agonists.  Management: Avoid concomitant use of opioid agonists and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Orphenadrine: CNS Depressants may enhance the CNS depressant effect of Orphenadrine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxomemazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxybate Salt Products: CNS Depressants may enhance the CNS depressant effect of Oxybate Salt Products.  Management: Consider alternatives to this combination when possible. If combined, dose reduction or discontinuation of one or more CNS depressants (including the oxybate salt product) should be considered. Interrupt oxybate salt treatment during short-term opioid use<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">OxyCODONE: CNS Depressants may enhance the CNS depressant effect of OxyCODONE.  Management: Avoid concomitant use of oxycodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Perampanel: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Piribedil: CNS Depressants may enhance the CNS depressant effect of Piribedil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prilocaine: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Prilocaine. Combinations of these agents may increase the likelihood of significant methemoglobinemia.  Management: Monitor patients for signs of methemoglobinemia (e.g., hypoxia, cyanosis) when prilocaine is used in combination with other agents associated with development of methemoglobinemia.  Avoid lidocaine/prilocaine in infants receiving such agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Procarbazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ropeginterferon Alfa-2b: CNS Depressants may enhance the adverse/toxic effect of Ropeginterferon Alfa-2b. Specifically, the risk of neuropsychiatric adverse effects may be increased.  Management: Avoid coadministration of ropeginterferon alfa-2b and other CNS depressants. If this combination cannot be avoided, monitor patients for neuropsychiatric adverse effects (eg, depression, suicidal ideation, aggression, mania).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rufinamide: May enhance the adverse/toxic effect of CNS Depressants. Specifically, sleepiness and dizziness may be enhanced.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Nitrite: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Sodium Nitrite. Combinations of these agents may increase the likelihood of significant methemoglobinemia. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Suvorexant: CNS Depressants may enhance the CNS depressant effect of Suvorexant.  Management: Dose reduction of suvorexant and/or any other CNS depressant may be necessary.  Use of suvorexant with alcohol is not recommended, and the use of suvorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thalidomide: CNS Depressants may enhance the CNS depressant effect of Thalidomide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Trimeprazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Valerian: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem adult dose to 1.75 mg for  men who are also receiving other CNS depressants. No such dose change is recommended for women. Avoid use with other CNS depressants at bedtime; avoid use with alcohol.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zuranolone: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to the use of zuranolone with other CNS depressants or alcohol. If combined, consider a zuranolone dose reduction and monitor patients closely for increased CNS depressant effects.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block rep_considerations drugH1Div" id="F49308549"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Infertility has been reported following prolonged occupational exposure. This risk is related to dose and duration of exposure and is decreased with proper administration procedures (Becker 2008; Rooks 2011; Zafirova 2018).</p></div>
<div class="block pri drugH1Div" id="F14191241"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Nitrous oxide crosses the placenta.</p>
<p style="text-indent:0em;margin-top:2em;">Concentrations of nitrous oxide in the fetal circulation are ~80% of those in the maternal plasma. The half-life in the neonate is ~3 minutes and it is quickly eliminated from neonatal lungs with the onset of breathing (Rooks 2011).</p>
<p style="text-indent:0em;margin-top:2em;">Spontaneous abortion and congenital abnormalities have been reported in health care providers following prolonged occupational exposure (Becker 2008; Brodsky 1986; Rooks 2011). However, these adverse events are related to dose and duration of exposure and risks are decreased with proper administration procedures (Rooks 2011; Zafirova 2018). Short duration of exposure to the pregnant patients during obstetric procedural anesthesia is not associated with an increased risk of adverse events to the fetus (Neuman 2013).</p>
<p style="text-indent:0em;margin-top:2em;">Nitrous oxide is used in labor analgesia, as well as occasionally postpartum (ACOG 2019b; Collins [AWHONN 2018]; Likis 2014; Rooks 2011; Rosen 2002) and may be used when needed for dental treatments that cannot be postponed during pregnancy (or delayed until after the first trimester) (Becker 2008).</p>
<p style="text-indent:0em;margin-top:2em;">ACOG recommends that pregnant patients should not be denied medically necessary surgery, regardless of trimester. If the procedure is elective, it should be delayed until after delivery (ACOG 2019a).</p>
<p style="text-indent:0em;margin-top:2em;">Nitrous oxide administration may be considered an aerosol-generating procedure; therefore, use in labor analgesia may be of concern in patients with confirmed or unknown COVID-19 infection (Khan 2021; Pavlidis 2021). Consider suspending use of nitrous oxide for labor analgesia in patients with COVID-19 due to insufficient data related to physiologic safety. Patients who are confirmed to be COVID-19 negative may continue to be offered nitrous oxide as an option for labor analgesia (ACOG 2022).</p></div>
<div class="block brc drugH1Div" id="F51538568"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Nitrous oxide was not found to influence the initiation or continuation of breastfeeding when used during labor (Zanardo 2017).</p>
<p style="text-indent:-2em;margin-left:2em;">The Academy of Breastfeeding Medicine recommends postponing elective surgery until milk supply and breastfeeding are established. Milk should be expressed ahead of surgery when possible. In general, when the child is healthy and full term, breastfeeding may resume, or milk may be expressed once the mother is awake and in recovery. For children who are at risk for apnea, hypotension, or hypotonia, milk may be saved for later use when the child is at lower risk (ABM [Reece-Stremtan 2017]).</p></div>
<div class="block pha drugH1Div" id="F201323"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">General CNS depressant action; may act similar to inhaled general anesthetics by stabilizing axonal membranes to partially inhibit action potentials leading to sedation; may partially act on opiate receptor systems to cause mild analgesia; central sympathetic stimulating action supports blood pressure, systemic vascular resistance, and cardiac output; it does not depress carbon dioxide drive to breath. Nitrous oxide increases cerebral blood flow and intracranial pressure while decreasing hepatic and renal blood flow; has analgesic action similar to morphine.</p></div>
<div class="block phk drugH1Div" id="F201333"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Onset of action: Inhalation: 2-5 minutes </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Absorption: Rapid via lungs; blood/gas partition coefficient is 0.47 </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Metabolism: Body: &lt;0.004% </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Excretion: Primarily exhaled gases; skin (minimal amounts)</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F6038705"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Azoto protossido ossigas</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Nitrous oxide chugai</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Medisinsk lystgass | Medisinsk lystgass Praxair | Niontix</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Niontix</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Nitrogen oxydulatum</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Medicinsk lustgas air liquide | Niontix</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-30913200">
<a name="30913200"></a>American College of Obstetricians and Gynecologists (ACOG). ACOG committee opinion no. 775: nonobstetric surgery during pregnancy. <i>Obstet Gynecol</i>. 2019a;133(4):e285-e286.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitrous-oxide-drug-information/abstract-text/30913200/pubmed" id="30913200" target="_blank">30913200</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30801474">
<a name="30801474"></a>American College of Obstetricians and Gynecologists (ACOG). ACOG practice bulletin no. 209: obstetric analgesia and anesthesia. <i>Obstet Gynecol</i>. 2019b;133(3):e208-e225.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitrous-oxide-drug-information/abstract-text/30801474/pubmed" id="30801474" target="_blank">30801474</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  American College of Obstetricians and Gynecologists (ACOG). COVID-19 FAQs for obstetrician-gynecologists, obstetrics. https://www.acog.org/clinical-information/physician-faqs/covid-19-faqs-for-ob-gyns-obstetrics. Accessed April 7, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15829394">
<a name="15829394"></a>Bahn EL, Holt KR. Procedural sedation and analgesia: a review and new concepts. <i>Emerg Med Clin North Am</i>. 2005;23(2):503-517. doi:10.1016/j.emc.2004.12.013<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitrous-oxide-drug-information/abstract-text/15829394/pubmed" id="15829394" target="_blank">15829394</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19108597">
<a name="19108597"></a>Becker DE and Rosenberg M, "Nitrous Oxide and the Inhalation Anesthetics," <i>Anesth Prog</i>, 2008, 55(4):124-30.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitrous-oxide-drug-information/abstract-text/19108597/pubmed" id="19108597" target="_blank">19108597</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3537624">
<a name="3537624"></a>Brodsky JB and Cohen EN, "Adverse Effects of Nitrous Oxide," <i>Med Toxicol</i>, 1986, 1(5):362-74.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitrous-oxide-drug-information/abstract-text/3537624/pubmed" id="3537624" target="_blank">3537624</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30916011">
<a name="30916011"></a>Buhre W, Disma N, Hendrickx J, et al. European Society of Anaesthesiology task force on nitrous oxide: a narrative review of its role in clinical practice. <i>Br J Anaesth</i>. 2019;122(5):587-604. doi:10.1016/j.bja.2019.01.023<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitrous-oxide-drug-information/abstract-text/30916011/pubmed" id="30916011" target="_blank">30916011</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29628059">
<a name="29628059"></a>Collins M. Use of nitrous oxide in maternity care: AWHONN practice brief number 6. <i>Nurs Womens Health</i>. 2018;22(2):195-198.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitrous-oxide-drug-information/abstract-text/29628059/pubmed" id="29628059" target="_blank">29628059</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12441721">
<a name="12441721"></a>Fu AD, McDonald HR, Elliot D, et al. Complications of general anesthesia using nitrous oxide in eyes with pre-existing gas bubbles. <i>Retina.</i> 2002;22:569-74.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitrous-oxide-drug-information/abstract-text/12441721/pubmed" id="12441721" target="_blank">12441721</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Gropper.1">
<a name="Gropper.1"></a>Gropper M, Eriksson L, Fleisher L, Wiener-Kronish J, Cohen N, Leslie K. <i>Miller's Anesthesia</i>. 9th ed, vol 2. Elsevier; 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34402480">
<a name="34402480"></a>Khan A, Patrick A, Patil V, Nnochiri A, Wijayatilake S. The obstetric patient in the Covid pandemic: anaesthesia and perioperative care. <i>Curr Opin Obstet Gynecol</i>. 2021;33(5):361-369. doi:10.1097/GCO.0000000000000732<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitrous-oxide-drug-information/abstract-text/34402480/pubmed" id="34402480" target="_blank">34402480</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15220168">
<a name="15220168"></a>Lee EJK. Use of nitrous oxide causing severe visual loss 37 days after retinal surgery. <i>Br J Anaesthes.</i> 2004;93(3):464-6.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitrous-oxide-drug-information/abstract-text/15220168/pubmed" id="15220168" target="_blank">15220168</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24356165">
<a name="24356165"></a>Likis FE, Andrews JC, Collins MR, et al. Nitrous oxide for the management of labor pain: a systematic review. <i>Anesth Analg</i>. 2014;118(1):153-167. doi: 10.1213/ANE.0b013e3182a7f73c.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitrous-oxide-drug-information/abstract-text/24356165/pubmed" id="24356165" target="_blank">24356165</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Miller RD, <i>Miller’s Anesthesia</i>, 7th ed, Philadelphia PA: Churchill Livingstone, 2010.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26904965">
<a name="26904965"></a>Myles PS, Chan MT, Kasza J, et al. Severe nausea and vomiting in the evaluation of nitrous oxide in the gas mixture for anesthesia II trial. <i>Anesthesiology</i>. 2016;124(5):1032-1040. doi:10.1097/ALN.0000000000001057<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitrous-oxide-drug-information/abstract-text/26904965/pubmed" id="26904965" target="_blank">26904965</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17667565">
<a name="17667565"></a>Myles PS, Leslie K, Chan MT, et al; ENIGMA Trial Group. Avoidance of nitrous oxide for patients undergoing major surgery: a randomized controlled trial. <i>Anesthesiology</i>. 2007;107(2):221-231. doi:10.1097/01.anes.0000270723.30772.da<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitrous-oxide-drug-information/abstract-text/17667565/pubmed" id="17667565" target="_blank">17667565</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25142708">
<a name="25142708"></a>Myles PS, Leslie K, Chan MT, et al; ANZCA Trials Group for the ENIGMA-II investigators. The safety of addition of nitrous oxide to general anaesthesia in at-risk patients having major non-cardiac surgery (ENIGMA-II): a randomised, single-blind trial. <i>Lancet</i>. 2014;384(9952):1446-1454. doi:10.1016/S0140-6736(14)60893-X<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitrous-oxide-drug-information/abstract-text/25142708/pubmed" id="25142708" target="_blank">25142708</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23470068">
<a name="23470068"></a>Neuman G, Koren G. Safety of procedural sedation in pregnancy. <i>J Obstet Gynaecol Can</i>. 2013;35(2):168-173. doi: 10.1016/S1701-2163(15)31023-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitrous-oxide-drug-information/abstract-text/23470068/pubmed" id="23470068" target="_blank">23470068</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7762371">
<a name="7762371"></a>Ohryn M. Tympanic membrane rupture following general anesthesia with nitrous oxide: A case report. <i>AANA J</i>. 1995;63(1):42-44.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitrous-oxide-drug-information/abstract-text/7762371/pubmed" id="7762371" target="_blank">7762371</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33191126">
<a name="33191126"></a>Pavlidis P, Eddy K, Phung L, et al. Clinical guidelines for caring for women with COVID-19 during pregnancy, childbirth and the immediate postpartum period. <i>Women Birth</i>. 2021;34(5):455-464. doi:10.1016/j.wombi.2020.10.015<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitrous-oxide-drug-information/abstract-text/33191126/pubmed" id="33191126" target="_blank">33191126</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29624435">
<a name="29624435"></a>Reece-Stremtan S, Campos M, Kokajko L; Academy of Breastfeeding Medicine. ABM clinical protocol #15: analgesia and anesthesia for the breastfeeding mother, revised 2017. <i>Breastfeed Med</i>. 2017;12(9):500-506.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitrous-oxide-drug-information/abstract-text/29624435/pubmed" id="29624435" target="_blank">29624435</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22060215">
<a name="22060215"></a>Rooks JP, "Safety and Risks of Nitrous Oxide Labor Analgesia: A Review," <i>J Midwifery Womens Health</i>, 2011, 56(6):557-65.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitrous-oxide-drug-information/abstract-text/22060215/pubmed" id="22060215" target="_blank">22060215</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12011877">
<a name="12011877"></a>Rosen MA. Nitrous oxide for relief of labor pain: a systematic review. <i>Am J Obstet Gynecol</i>. 2002;186(5 Suppl):S110-S126.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitrous-oxide-drug-information/abstract-text/12011877/pubmed" id="12011877" target="_blank">12011877</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Sprehn M, Faber T, Osgaard O. Life-threatening tension pneumocephalus after nitrous oxide anaesthesia. <i>Anaesthesia</i>. 1992 Feb;47(2):174.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26545294">
<a name="26545294"></a>Sun R, Jia WQ, Zhang P, et al. Nitrous oxide-based techniques versus nitrous oxide-free techniques for general anaesthesia. <i>Cochrane Database Syst Rev</i>. 2015;(11):CD008984. doi:10.1002/14651858.CD008984.pub2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitrous-oxide-drug-information/abstract-text/26545294/pubmed" id="26545294" target="_blank">26545294</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30322453">
<a name="30322453"></a>Zafirova Z, Sheehan C, Hosseinian L. Update on nitrous oxide and its use in anesthesia practice. <i>Best Pract Res Clin Anaesthesiol</i>. 2018;32(2):113-123.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitrous-oxide-drug-information/abstract-text/30322453/pubmed" id="30322453" target="_blank">30322453</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28814150">
<a name="28814150"></a>Zanardo V, Volpe F, Parotto M, Giiberti L, Selmin A, Straface G. Nitrous oxide labor analgesia and pain relief memory in breastfeeding women. <i>J Matern Fetal Neonatal Med</i>. 2017:1-6. doi: 10.1080/14767058.2017.1368077.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitrous-oxide-drug-information/abstract-text/28814150/pubmed" id="28814150" target="_blank">28814150</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 10086 Version 184.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
